These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24375668)

  • 1. Factors predictive of the development of levodopa-induced dyskinesia and Wearing-Off in Parkinson's disease.
    Rajput AH
    Mov Disord; 2014 Mar; 29(3):429. PubMed ID: 24375668
    [No Abstract]   [Full Text] [Related]  

  • 2. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiating levodopa therapy for Parkinson's disease.
    Olanow CW; Kieburtz K; Stocchi F
    Mov Disord; 2014 Mar; 29(3):430. PubMed ID: 24408661
    [No Abstract]   [Full Text] [Related]  

  • 4. Rating scales for dyskinesias in Parkinson's disease.
    Goetz CG
    Mov Disord; 1999; 14 Suppl 1():48-53. PubMed ID: 10493403
    [No Abstract]   [Full Text] [Related]  

  • 5. Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
    Chaudhuri KR; Jenner P; Antonini A
    Mov Disord; 2019 Jun; 34(6):816-819. PubMed ID: 30983023
    [No Abstract]   [Full Text] [Related]  

  • 6. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease.
    Vidailhet M; Bonnet AM; Marconi R; Durif F; Agid Y
    Mov Disord; 1999; 14 Suppl 1():13-8. PubMed ID: 10493399
    [No Abstract]   [Full Text] [Related]  

  • 7. Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):198-200. PubMed ID: 29186084
    [No Abstract]   [Full Text] [Related]  

  • 8. Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy.
    Kim JM; Lee KH; Choi YL; Choe GY; Jeon BS
    Mov Disord; 2002 Sep; 17(5):1089-90. PubMed ID: 12360566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Web Resource for Levodopa-Induced Dyskinesia Genetics in Parkinson's Disease.
    Blankenburg H; Falla M; Schwienbacher C; Fabbrini G; Berardelli A; Pramstaller PP; Domingues FS
    Neuroinformatics; 2017 Jul; 15(3):297-300. PubMed ID: 28417316
    [No Abstract]   [Full Text] [Related]  

  • 10. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.
    Rascol O
    Mov Disord; 1999; 14 Suppl 1():19-32. PubMed ID: 10493400
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.
    Mizuno Y; Shimoda S; Origasa H
    J Neural Transm (Vienna); 2018 Jan; 125(1):35-43. PubMed ID: 28091751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease.
    Onofrj M; Paci C; Thomas A
    J Neurol Neurosurg Psychiatry; 1998 Oct; 65(4):605-6. PubMed ID: 9771801
    [No Abstract]   [Full Text] [Related]  

  • 13. Coffee consumption and risk of levodopa-induced dyskinesia in Parkinson's disease: The FRAGAMP study.
    Nicoletti A; Zappia M;
    Mov Disord; 2015 Nov; 30(13):1854-6. PubMed ID: 26769461
    [No Abstract]   [Full Text] [Related]  

  • 14. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 15. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimising levodopa therapy for the management of Parkinson's disease.
    Stocchi F
    J Neurol; 2005 Oct; 252 Suppl 4():IV43-IV48. PubMed ID: 16222437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ropinirole as compared with levodopa in Parkinson's disease.
    Weiner WJ; Factor SA
    N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001687
    [No Abstract]   [Full Text] [Related]  

  • 19. A unified dyskinesias rating scale for L-dopa-induced dyskinesias?
    Nutt J
    Mov Disord; 1999; 14 Suppl 1():74. PubMed ID: 10493408
    [No Abstract]   [Full Text] [Related]  

  • 20. Ropinirole as compared with levodopa in Parkinson's disease.
    Frucht S
    N Engl J Med; 2000 Sep; 343(12):885. PubMed ID: 11001686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.